There’s hope for patients with myotonic dystrophy. A new small molecule developed by researchers at the University of Illinois has been shown to break up the protein-RNA clusters that cause the disease in living human cells, an important first step toward developing a pharmaceutical treatment for the as-yet untreatable disease.
Steven C. Zimmerman, the Roger Adams Professor of Chemistry at the U. of I., led the group in developing and demonstrating the compound. The National Institutes of Health supported the work published in the journal ACS Chemical Biology.
Myotonic dystrophy type 1 is the most common form of muscular dystrophy in adults, affecting one in 8,000 people in North America. It causes progressive weakness as the muscles deteriorate over time. There is no treatment available for the disease; though a few measures can help ease some symptoms, nothing can halt their inevitable progression.
“This is a disease that currently doesn’t have any treatment, so we have a huge interest in finding therapeutic agents,” said graduate student Amin Haghighat Jahromi, the first author of the paper.
Myotonic dystrophy type 1, called DM1 for short, is caused by a mutation to one gene. In a healthy person, one small segment of the gene – a DNA sequence of CTG – is repeated a few times. In someone with DM1, the sequence is repeated more than 50 times, even up to thousands of repeats. The sequence is transcribed into RNA over and over, like a skipping record stuck in a loop. The repetitive RNA binds to the protein MBNL1, which is essential for regulating protein balance in cells. The RNA traps the MBNL1 protein in aggregates within the cell’s nucleus.
“The RNA is functioning in an abnormal way, and unfortunately, it’s toxic,” Zimmerman said. “MNBL regulates a process called alternative splicing that controls how much of different proteins are made. Affected cells make the proteins, just not at the right levels, so all the levels are imbalanced. There are more than 100 proteins that are affected.”
The Illinois group developed a small molecule that could infiltrate the nucleus and bind to the RNA, forcing it to let go of MBNL1 so the protein can do its job. The molecule is small and water-soluble so it can cross the membrane into the cell, which has been a challenge for researchers attempting to use methods with larger molecules. It specifically targets only the repeating RNA sequence so as not to interfere with other cellular functions.
The researchers administered the molecule to live cells that have the disease features of DM1. Using advanced microscopy methods, they were able to watch the cells over time to see how they responded to the molecule. In only a few hours, they saw the clusters within the nucleus break up and were able to measure that the MBNL1 protein had increased its regulatory activity.
“This is the first study that gives direct evidence for the function of the compound,” Jahromi said. “We track how the cell is changing upon treatment with the compound and see the effect directly.”
Next, the researchers plan to begin collaborating with other groups to test their molecule in fruit flies and mice. Although the molecule will need many rounds of testing for toxicity, efficacy, metabolism and possible side effects before human trials can begin, finding a molecule that works in living cells is an important first step toward making a drug that could treat myotonic dystrophy.
The Latest Bing News on:
Muscular dystrophy treatment
- Here is where you can find Chattanooga firefighters for Fill the Booton May 10, 2024 at 5:26 pm
Firefighters across the nation are participating in the Fill-the-Boot campaign to raise funds for the Muscular Dystrophy Association.
- Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Runon May 10, 2024 at 10:49 am
Edgewise reveals strong cash position and progressing clinical-stage programs, sparking a bull run. Find out why this is a good time to sell EWTX stock.
- Jerry R. Mendell makes TIME100 Health list for pioneering researchon May 10, 2024 at 6:21 am
Jerry R. Mendell, MD, has been named to the TIME100 Health list for his contributions to the treatment of neuromuscular diseases.
- Rabbi Yosef Zvi Rimon: Influencing the fate of millions with muscular dystrophyon May 10, 2024 at 6:15 am
O ne Saturday night while Rabbi Yosef Zvi Rimon was teaching a group of seminary students at his house in Alon Shvut, there was a knock at the door. Tentatively, he opened it and ...
- Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demandson May 9, 2024 at 4:59 pm
With SOC treatment alone, caregivers were estimated to lose 7194 ... Characterizing the experience of caregiving for those with Duchenne muscular dystrophy (DMD): results from a cross-sectional survey ...
- Using curiosity to make a difference: how one Ph.D. candidate found her ‘why’on May 9, 2024 at 4:59 pm
I work on LAMA2-CMD, a very rare congenital muscular dystrophy in which patients ultimately die within the first or second decade of life. There currently is no effective treatment or cure. It is ...
- ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progresson May 9, 2024 at 7:00 am
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
- Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trialon May 8, 2024 at 10:09 am
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to ...
- Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trialon May 7, 2024 at 11:19 pm
Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death of a young ...
- Young boy dies in trial for Pfizer Duchenne gene therapyon May 7, 2024 at 2:57 pm
A boy with Duchenne muscular dystrophy died after receiving a Pfizer experimental gene therapy. The company is pausing its trial in older boys.
The Latest Google Headlines on:
Muscular dystrophy treatment
[google_news title=”” keyword=”muscular dystrophy treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Muscular dystrophy
- Here is where you can find Chattanooga firefighters for Fill the Booton May 10, 2024 at 5:26 pm
Firefighters across the nation are participating in the Fill-the-Boot campaign to raise funds for the Muscular Dystrophy Association.
- Annual ‘Fill the Boot’ campaign kicks off this weekend for the Muscular Dystrophy Associationon May 10, 2024 at 3:00 pm
Local firefighters will once again be lining the streets to ask for your help in collecting funds for the Muscular Dystrophy Association. The Fill the Boot campaign kicks off this weekend as the ...
- A $17.3 Million Patek Philippe Minute Repeater Leads Only Watch Auctionon May 10, 2024 at 12:11 pm
Originally scheduled for November 5 th 2023, a group of online publications and collectors had started to ask uncomfortable questions on social media about how the €100 million already raised was ...
- Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Runon May 10, 2024 at 10:49 am
Edgewise reveals strong cash position and progressing clinical-stage programs, sparking a bull run. Find out why this is a good time to sell EWTX stock.
- Rabbi Yosef Zvi Rimon: Influencing the fate of millions with muscular dystrophyon May 10, 2024 at 6:15 am
O ne Saturday night while Rabbi Yosef Zvi Rimon was teaching a group of seminary students at his house in Alon Shvut, there was a knock at the door. Tentatively, he opened it and ...
- Using curiosity to make a difference: how one Ph.D. candidate found her ‘why’on May 9, 2024 at 4:59 pm
I work on LAMA2-CMD, a very rare congenital muscular dystrophy in which patients ultimately die within the first or second decade of life. There currently is no effective treatment or cure. It is ...
- HHS panel to vote in Nov. on DMD screening for newbornson May 9, 2024 at 3:44 pm
An HHS advisory committee is expected to vote this fall on whether to recommend newborns be screened for Duchenne muscular dystrophy, or DMD. Read more here.
- ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progresson May 9, 2024 at 7:00 am
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
- Young Patient Dies After Receiving Pfizer Gene Therapyon May 9, 2024 at 6:13 am
Tragedy has struck during an important Pfizer medical trial when a young boy suffered a fatal sudden cardiac arrest after receiving experimental gene therapy, according to Reuters, and this death has ...
- Help Chattanooga firefighters 'Fill the Boot' in support of Muscular Dystrophy Associationon May 8, 2024 at 8:18 am
It’s that time of year where firefighters nationwide are joining forces to "Fill the Boot" for the Muscular Dystrophy Association.The Chattanooga Fire Departmen ...
The Latest Google Headlines on:
Muscular dystrophy
[google_news title=”” keyword=”muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]